Amifostine in reducing cisplatin toxicity.

Author(s): Markman M

Affiliation(s): The Cleveland Clinic Cancer Center and the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.

Publication date & source: 1998-10, Semin Oncol., 25(5):522-4.

Publication type: Review

Amifostine has been demonstrated in preclinical evaluation and through the conduct of a randomized controlled clinical trial to reduce the incidence and severity of cisplatin-associated toxicity. While the role of amifostine in standard oncologic management remains to be defined, patients who require treatment with cisplatin who have preexisting renal or neurologic dysfunction may have their potential for further damage to these organs reduced if amifostine is delivered along with the cytotoxic drug.